1386861-47-7

Basic information

• Product Name: tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)phenyl)-3-oxobutane-2-yl)carbamate
• Synonyms: tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)phenyl)-3-oxobutane-2-yl)carbamate
• CAS NO: 1386861-47-7
• Molecular Weight: 416.904
• Mol File: 1386861-47-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)phenyl)-3-oxobutane-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)phenyl)-3-oxobutane-2-yl)carbamate(1386861-47-7)
• EPA Substance Registry System: tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)phenyl)-3-oxobutane-2-yl)carbamate(1386861-47-7)

Safety Data

• Hazardous Substances Data: 1386861-47-7(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 28875-17-4 (S)-N-(tert-butoxycarbonyl)alanine methyl ester 
• 1386861-46-6 2-chloro-6-methyl-N-phenylbenzamide 
• 146553-06-2 tert-butyl {(S)-1-[methoxy(methyl)amino]-1-oxopropan-2-yl}carbamate 
• 1420625-93-9 C₁₆H₂₀ClNO₅ 
• 125218-78-2 tert-butyl (S)-[1-(dimethylamino)-1-oxopropan-2-yl]carbamate 
• 1420625-96-2 (S)-tert-butyl 1-(8-chloro-1-oxo-1H-isochromen-3-yl)ethylcarbamate 
• 62-53-3 aniline 
• 15761-38-3 L-N-Boc-Ala 
• 89894-44-0 2-chloro-6-methylbenzoyl chloride 
• 21327-86-6 2-chloro-6-methylbenzoic acid 

Downstream Products

• 1350643-72-9 (S)-3-(1-aminoethyl)-8-chloro-2-phenylisoquinoline-1(2H)-one 
• 1350643-73-0 8-chloro-2-phenyl-3-((1S)-1-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one 
• 1201438-56-3 (S)-3-(1-((9H-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one 
• 1466565-90-1 (S)-N-(1-(8-chloro-1-oxo-2-phenyl-1,2-dihydroisoquinoline-3-yl)ethyl)-2,2,2-trifluoroacetamide 

Relevant articles and documents

PHOSPHOINOSITIDE 3-KINASE AND SRC INHIBITORS FOR TREATMENT OF PANCREATIC CANCER

A phosphoinositide 3-kinase inhibitor for use in the treatment of pancreatic cancer and a method for treatment of pancreatic cancer including administration of an phosphoinositide 3-kinase inhibitor an Src inhibitor to a human subject in need thereof. There is also provided a pharmaceutical composition comprising a phosphoinositide 3-kinase inhibitor and an Src inhibitor.

SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE

The invention relates to the preparation and use of new aminopyrirnidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the

QUINAZOLINE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.